

Publisher: American Chemical Society.

AB Even though most eucaryotic proteins are glycosylated, very little is known on if, or how, the glycans influence essential immunol. events such as antigen processing, major histocompatibility complex (MHC) restricted presentation, and recognition by T cells. The authors have used synthetic glycopeptides to elucidate the specificity of T cell hybridomas, obtained by immunization with the glycoprotein type II collagen in a mouse model for rheumatoid arthritis. To enable these studies, glycosylated and suitably protected derivs. of (5R)-5-hydroxy-L-lysine, and the similar 5-hydroxy-L-norvaline, were prepd. and then used in Fmoc solid-phase synthesis of glycopeptides related to the immunodominant fragment from type II collagen, CII(256-270). Evaluation of the synthetic glycopeptides provided evidence that antigen-presenting cells can indeed process glycoproteins to glycopeptides, which elicit a T cell response when presented by class II MHC mols. A glycopeptide carrying a single .beta.-D-galactosyl residue attached to hydroxylysine at position 264 in the center of the CII(256-270) peptide was recognized by most of the hybridomas in a way involving specific contacts between the **carbohydrate** and the T cell receptor. The results suggest an explanation for the recent observation that glycosylated type II collagen induces more severe forms of arthritis in the mouse than deglycosylated type II collagen and provide addnl. knowledge on how rheumatoid arthritis may occur also in humans.

FILE 'REGISTRY' ENTERED AT 16:26:53 ON 05 NOV 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1998 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 31 OCT 98 HIGHEST RN 213527-24-3
DICTIONARY FILE UPDATES: 04 NOV 98 HIGHEST RN 213527-24-3

TSCA INFORMATION NOW CURRENT THROUGH JUNE 29, 1998

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Stereochemical name changes have been adopted and appear in CN's
beginning 6/29/98. See the online news message for details.

=> e dendrimeric poly-lysine/cn

E1	1	DENDRILLOLIDE D/CN
E2	1	DENDRILLOLIDE E/CN
E3	0 -->	DENDRIMERIC POLY-LYSINE/CN
E4	1	DENDRINE/CN
E5	1	DENDRINOLIDE/CN
E6	1	DENDRITIC CELL DISINTEGRIN-METALLOPROTEINASE/CN
E7	1	DENDRITIC CELL DISINTEGRIN-METALLOPROTEINASE (HUMAN)/C N
E8	1	DENDRITIC CELL-DERIVED GROWTH FACTOR (HUMAN CLONE HDPM J44 PRECURSOR)/CN
E9	1	DENDRITIC CELL-DERIVED GROWTH FACTOR (HUMAN CLONE HDPM J44)/CN
E10	1	DENDRO/CN
E11	1	DENDROAMIDE A/CN
E12	1	DENDROAMIDE B/CN

=> s dendrimeric(1) poly-lysine

0 DENDRIMERIC
707621 POLY
39457 LYSINE
29 POLY-LYSINE
(POLY(W)LYSINE)
L1 0 DENDRIMERIC(L) POLY-LYSINE

=> s dendrimeric(1) poly lysine

Achutamurthy
049847

0 DENDRIMERIC
707621 POLY
39457 LYSINE
29 POLY LYSINE
(POLY(W)LYSINE)
L2 0 DENDRIMERIC(L) POLY LYSINE

=> fil caplus,.biotech,wpids,uspatful;s (poly lysine or
polylysine)(l)dendrimer?

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.68	119.01
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.03

FILE 'CAPLUS' ENTERED AT 16:29:19 ON 05 NOV 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1998 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:29:19 ON 05 NOV 1998
COPYRIGHT (C) 1998 BIOSIS(R)

FILE 'MEDLINE' ENTERED AT 16:29:19 ON 05 NOV 1998

FILE 'EMBASE' ENTERED AT 16:29:19 ON 05 NOV 1998
COPYRIGHT (C) 1998 Elsevier Science B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:29:19 ON 05 NOV 1998
COPYRIGHT (C) 1998 DERWENT INFORMATION LTD

FILE 'USPATFULL' ENTERED AT 16:29:19 ON 05 NOV 1998
CA INDEXING COPYRIGHT (C) 1998 AMERICAN CHEMICAL SOCIETY (ACS)

L3 19 FILE CAPLUS
L4 5 FILE BIOSIS
L5 6 FILE MEDLINE
L6 7 FILE EMBASE
L7 3 FILE WPIDS
L8 39 FILE USPATFULL

TOTAL FOR ALL FILES

L9 79 (POLY LYSINE OR POLYLYSINE) (L) DENDRIMER?

=> s 19 and carbohydrate peptide

L10 1 FILE CAPLUS
L11 0 FILE BIOSIS
L12 0 FILE MEDLINE
L13 0 FILE EMBASE
L14 0 FILE WPIDS
L15 0 FILE USPATFULL

TOTAL FOR ALL FILES

L16 1 L9 AND CARBOHYDRATE PEPTIDE

=> d cbib abs;s l9 and t epitope?

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1998 ACS

1998:682157 Multiple antigen glycopeptide carbohydrate, vaccine comprising it and its use. Bay, Sylvie; Cantacuzene, Daniele; Leclerc, Claude; Lo-Man, Richard (Institut Pasteur, Fr.). PCT Int. Appl. WO 9843677 A1 19981008, 55 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 98-EP1922 19980327. PRIORITY: US 97-41726 19970327.

AB A **carbohydrate peptide** conjugate comprising: a carrier comprising a **dendrimeric poly-Lysine** enabling multiple epitopes to be covalently attached thereto, at least one peptide comprising one T epitope or several identical or different T epitopes, at least one carbohydrate moiety, or a deriv. thereof, contg. B epitope, provided it is not a sialoside, or several identical or different epitopes. Use of this conjugate for inducing immune response.

L17	1 FILE CAPLUS
L18	0 FILE BIOSIS
L19	0 FILE MEDLINE
L20	0 FILE EMBASE
L21	0 FILE WPIDS
L22	0 FILE USPATFULL

Priority

TOTAL FOR ALL FILES

L23 1 L9 AND T EPITOPE?

=> s l23 not l16

L24	0 FILE CAPLUS
L25	0 FILE BIOSIS
L26	0 FILE MEDLINE
L27	0 FILE EMBASE
L28	0 FILE WPIDS
L29	0 FILE USPATFULL

TOTAL FOR ALL FILES

L30 0 L23 NOT L16

=> s lysine and epitope and carbohydrate?

L31	27 FILE CAPLUS
L32	11 FILE BIOSIS
L33	30 FILE MEDLINE
L34	10 FILE EMBASE
L35	1 FILE WPIDS
L36	880 FILE USPATFULL

TOTAL FOR ALL FILES

L37 959 LYSINE AND EPITOPE AND CARBOHYDRATE?

=> s l37 and galactosyl(1)acetyl(1)sdrine

L38 0 FILE CAPLUS

L39 0 FILE BIOSIS

<-----User Break----->

u

SEARCH ENDED BY USER

SEARCH ENDED BY USER

=> s 137 and galactosyl(1)acetyl(1)serine

L41 0 FILE CAPLUS

L42 0 FILE BIOSIS

L43 0 FILE MEDLINE

L44 0 FILE EMBASE

L45 0 FILE WPIDS

L46 11 FILE USPATFULL

TOTAL FOR ALL FILES

L47 11 L37 AND GALACTOSYL(L) ACETYL(L) SERINE

=> d 1-11 cbib abs;s 137 and (galactosyl or glycosyl)

L47 ANSWER 1 OF 11 USPATFULL

1998:101524 Glycosyltransferases for biosynthesis of oligosaccharides,
and genes encoding them.

Gotschlich, Emil C., New York, NY, United States

The Rockefeller University, New York, NY, United States (U.S.
corporation)

US 5798233 980825

APPLICATION: US 96-683458 960718 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to nucleic acids encoding
glycosyltransferases, the proteins encoded thereby, and to methods
for synthesizing oligosaccharides using the glycosyltransferases
of the invention. In particular, the present application is
directed to identification a glycosyltransferase locus of
Neisseria gonorrhoeae containing five open reading frames for five
different glycosyltransferases. The functionally active
glycosyltransferases of the invention are characterized by
catalyzing reactions such as adding Gal .beta.1.fwdarw.4 to GlcNAc
or Glc; adding GalNAc or GlcNAc .beta.1.fwdarw.3 to Gal; and
adding Gal .alpha.1.fwdarw.4 to Gal. The glycosyltransferases of
the invention are particularly suited to the synthesis of the
oligosaccharides Gal.beta.1.fwdarw.4GlcNAc
.beta.1.fwdarw.3Gal.beta.1.fwdarw.4Glc (a mimic of
lacto-N-neotetraose), GalNAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4Glc
NAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4Glc.beta.1.fwdarw.4 (a mimic
ganglioside), and Gal.alpha.1.fwdarw.4Gal.beta.1.fwdarw.4Glc.beta.
1.fwdarw.4Hep.fwdarw.R (a mimic of the saccharide portion of
globo-glycolipids).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 2 OF 11 USPATFULL

1998:72452 Methods and products for the synthesis of oligosaccharide
structures on glycoproteins, glycolipids, or as free molecules, and
for the isolation of cloned genetic sequences that determine these
structures.

Lowe, John B., Ann Arbor, MI, United States

Legault, Daniel J., Ann Arbor, MI, United States
The Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)
US 5770420 980623

APPLICATION: US 95-525058 950908 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for isolating a gene, comprising:

(i) isolating a cell possessing a post-translational characteristic of interest, said post-translational characteristic being the presence of a membrane-bound oligosaccharide or polysaccharide of interest on the surface of said cell, the presence of a soluble oligosaccharide or polysaccharide of interest in an extract of said cell, or the presence of a particularly glycosyltransferase activity in an extract of said cell;

(ii) creating a genetic library of either cDNA or genomic DNA from the genetic material of said isolated cell;

(iii) transforming host cells with said genetic library; and

(iv) screening said transformed host cells for a host cell containing said post-translational characteristic, thereby obtaining a cell containing said gene, is disclosed. The method can be used to obtain genes encoding glycosyltransferases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 3 OF 11 USPATFULL

1998:57716 Aptamers specific for biomolecules and methods of making.

Griffin, Linda, Atherton, CA, United States

Albrecht, Glenn, Redwood City, CA, United States

Latham, John, Palo Alto, CA, United States

Leung, Lawrence, Hillsborough, CA, United States

Vermaas, Eric, Oakland, CA, United States

Toole, John J., Burlingame, CA, United States

Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)

US 5756291 980526

APPLICATION: US 95-484192 950607 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for identifying oligomer sequences, optionally comprising modified base, which specifically bind target molecules such as serum proteins, kinins, eicosanoids and extracellular proteins is described. The method is used to generate aptamers that bind to serum Factor X, PDGF, FGF, ICAM, VCAM, E-selectin, thrombin, bradykinin, PGF2 and cell surface molecules. The technique involves complexation of the target molecule with a mixture of oligonucleotides containing random sequences and sequences which serve as primer for PCR under conditions wherein a complex is formed with the specifically binding sequences, but not with the other members of the oligonucleotide mixture. The complex is then separated from uncomplexed oligonucleotides and the complexed members of the oligonucleotide mixture are recovered from the separated complex using the polymerase chain reaction. The recovered oligonucleotides may be sequenced, and successive rounds of selection using complexation, separation, amplification and recovery can be employed. The oligonucleotides can be used for

therapeutic and diagnostic purposes and for generating secondary aptamers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 4 OF 11 USPATFULL

1998:54875 Intercellular adhesion mediators.

Paulson, James C., Sherman Oaks, CA, United States

Perez, Mary S., Carlsbad, CA, United States

Gaeta, Federico C. A., La Jolla, CA, United States

Ratcliffe, Robert M., Carlsbad, CA, United States

Cytel Corporation, San Diego, CA, United States (U.S. corporation)

US 5753631 980519

APPLICATION: US 95-457886 950531 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed towards compositions and methods for reducing or controlling inflammation and for treating inflammatory disease processes and other pathological conditions mediated by intercellular adhesion. The compositions of the invention include compounds that selectively bind selectin receptors, the selectin binding activity being mediated by a **carbohydrate** moiety. The selectin-binding moieties of the invention are derivatives of a sialylated, fucosylated N-acetyllactosamine unit of the Lewis X antigen. Compounds containing a selectin-binding moiety in both monovalent and multivalent forms are included in the invention. The compounds of the invention are provided as pharmaceutical compositions which include, for example, liposomes that carry selectin-binding moieties of the invention. The invention further includes immunoglobulins capable of selectively binding an oligosaccharide ligand that is recognized by a selectin receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 5 OF 11 USPATFULL

1998:1654 Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them.

Gotschlich, Emil C., New York, NY, United States

The Rockefeller University, New York, NY, United States (U.S. corporation)

US 5705367 980106

APPLICATION: US 96-683426 960718 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to nucleic acids encoding glycosyltransferases, the proteins encoded thereby, and to methods for synthesizing oligosaccharides using the glycosyltransferases of the invention. In particular, the present application is directed to identification a glycosyltransferase locus of *Neisseria gonorrhoeae* containing five open reading frames for five different glycosyltransferases. The functionally active glycosyltransferases of the invention are characterized by catalyzing reactions such as adding Gal .beta..fwdarw.4 to GlcNAc or Glc; adding GalNAc or GlcNAc .beta.1.fwdarw.3 to Gal; and adding Gal .alpha.1.fwdarw.4 to Gal. The glycosyltransferases of the invention are particularly suited to the synthesis of the oligosaccharides Gal.beta.1.fwdarw.4GlcNAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4Glc (a mimic of lacto-N-neotetraose), GalNAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4Glc.beta.1.fwdarw.4 (a mimic ganglioside), and

Gal.alpha.1.fwdarw.4Gal.beta.1.fwdarw.4Glc.beta.1.fwdarw.4Hep.fwda
rw.R (a mimic of the saccharide portion of globo-glycolipids).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 6 OF 11 USPATFULL

97:42628 Two-step pretargeting methods using improved biotin-active agent
conjugates.

Reno, John M., Brier, WA, United States

Theodore, Louis J., Lynnwood, WA, United States

Gustavson, Linda M., Seattle, WA, United States

NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

US 5630996 970520

APPLICATION: US 93-122979 930916 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to
pretargeted delivery of diagnostic and therapeutic agents are
disclosed. In particular, methods for radiometal labeling of
biotin and for improved radiohalogenation of biotin, as well as
related compounds, are described. Also, clearing agents,
anti-ligand-targeting moiety conjugates, target cell retention
enhancing moieties and additional methods are discussed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 7 OF 11 USPATFULL

97:36156 Clearing agents useful in pretargeting methods.

Axworthy, Donald B., Brier, WA, United States

Reno, John M., Brier, WA, United States

NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

US 5624896 970429

APPLICATION: US 95-462765 950605 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel clearing agents are provided which comprise biotin analog
containing clearance-directing moieties. Preferably such
clearance-directing moieties endogenously contain or a
rederivatized to expose galactose and/or mannose residues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 8 OF 11 USPATFULL

97:27275 Hexose derivatized human serum albumin clearing agents.

Axworthy, Donald B., Brier, WA, United States

Reno, John M., Brier, WA, United States

NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

US 5616690 970401

APPLICATION: US 93-133613 931008 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel clearing agents comprising hexose derivatized human serum
albumin and ligand molecule(s) are provided. These clearing agents
are useful in pretargeting methods to clear previously
administered anti-ligand containing conjugates. Preferably, the
hexose is mannose or galactose and the ligand and anti-ligand are
respectively biotin and avidin or streptavidin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 9 OF 11 USPATFULL

97:18284 Biotinidase-resistant biotin-DOTA conjugates.

Axworthy, Donald B., Brier, WA, United States
Theodore, Louis J., Lynnwood, WA, United States
Gustavson, Linda M., Seattle, WA, United States
Reno, John M., Brier, WA, United States
NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
US 5608060 970304
WO 9325240 931223
APPLICATION: US 95-351469 950221 (8)
WO 93-US5406 930607 950221 PCT 371 date 950221 PCT 102(e) date
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Biotinidase-resistant biotin-DOTA conjugates, and methods of use thereof in diagnostic and therapeutic pretargeting methods are provided. These conjugates are useful in diagnosis and treatment of cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 10 OF 11 USPATFULL

96:72801 Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them.

Gotschlich, Emil C., New York, NY, United States
The Rockefeller University, New York, NY, United States (U.S. corporation)
US 5545553 960813
APPLICATION: US 94-312387 940926 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to nucleic acids encoding glycosyltransferases, the proteins encoded thereby, and to methods for synthesizing oligosaccharides using the glycosyltransferases of the invention. In particular, the present application is directed to identification a glycosyltransferase locus of *Neisseria gonorrhoeae* containing five open reading frames for five different glycosyltransferases. The functionally active glycosyltransferases of the invention are characterized by catalyzing reactions such as adding Gal .beta.1.fwdarw.4 to GlcNAc or Glc; adding GalNAc or GlcNAc .beta.1.fwdarw.3 to Gal; and adding Gal .alpha.1.fwdarw.4 to Gal. The glycosyltransferases of the invention are particularly suited to the synthesis of the oligosaccharides Gal.beta.1.fwdarw.4GlcNAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4Glc (a mimic of lacto-N-neotetraose), GalNAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc.beta.1.fwdarw.3Gal .beta.1.fwdarw.4Glc.beta.1.fwdarw.4 (a mimic ganglioside), and Gal.alpha.1.fwdarw.4Gal.beta.1.fwdarw.4Glc.beta.1.fwdarw.4Hep.fwdarw.R (a mimic of the saccharide portion of globo-glycolipids).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 11 OF 11 USPATFULL

96:68105 Pretargeting methods and compounds.

Yau, Eric K., Kirkland, WA, United States
Theodore, Louis J., Lynnwood, WA, United States
Gustavson, Linda M., Seattle, WA, United States
NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
US 5541287 960730
APPLICATION: US 94-345811 941122 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to

pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Articles of manufacture useful in pretargeting methods are also discussed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 1 FILE CAPLUS
L49 0 FILE BIOSIS
L50 3 FILE MEDLINE
L51 0 FILE EMBASE
L52 0 FILE WPIDS
L53 123 FILE USPATFULL

TOTAL FOR ALL FILES

L54 127 L37 AND (GALACTOSYL OR GLYCOSYL)

=> s l54 and ((tumour or tumor)(w)antigen or vp1 or poliovirus type 1 or cd8 or neisser? meningit? or haemophil? influenz or streptococc? pneumon? or strpcoc? or tn antigen)

L55 0 FILE CAPLUS
L56 0 FILE BIOSIS
L57 0 FILE MEDLINE
L58 0 FILE EMBASE
L59 0 FILE WPIDS
L60 22 FILE USPATFULL

TOTAL FOR ALL FILES

L61 22 L54 AND ((TUMOUR OR TUMOR) (W) ANTIGEN OR VP1 OR POLIOVIRUS TYPE 1 OR CD8 OR NEISSER? MENINGIT? OR HAEMOPHIL? INFLUENZ OR STREPTOCOCC? PNEUMON? OR STRPCOC? OR TN ANTIGEN)

=> s l61 not (l47 or l16)

L62 0 FILE CAPLUS
L63 0 FILE BIOSIS
L64 0 FILE MEDLINE
L65 0 FILE EMBASE
L66 0 FILE WPIDS
L67 18 FILE USPATFULL

TOTAL FOR ALL FILES

L68 18 L61 NOT (L47 OR L16)

=> d 1-18 cbib abs;d 148 cbib abs;dis his

L68 ANSWER 1 OF 18 USPATFULL

1998:111801 Method of production of antigen-specific glycosylation inhibiting factor.

Ishizaka, Kimishige, La Jolla, CA, United States

Ishii, Yasuyuki, La Jolla, CA, United States

La Jolla Institute for Allergy and Immunology, San Diego, CA, United States (U.S. corporation)

US 5807714 980915

APPLICATION: US 95-416336 950404 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for the recombinant production and for the isolation of

antigen-specific glycosylation inhibiting factor (AgGIF) is provided. Also disclosed is a method for modulating the immune responses in an antigen-specific manner utilizing a AgGIF, comprising soluble non-specific GIF-TCR.alpha. chains which bind to the antigen, and which suppress the immune response in an antigen-specific fashion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 2 OF 18 USPATFULL

1998:111651 Compositions for generating T cell immunity against **carbohydrate** structures.

Jondal, Mikael, Stockholm, Sweden

Astra Aktiebolag, Sodertalje, Sweden (non-U.S. corporation)

US 5807559 980915

APPLICATION: US 93-54860 930427 (8)

PRIORITY: SE 92-1338 920428

SE 92-2553 920907

SE 92-3897 921223

SE 93-1141 930406

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel class of immunologically active compounds, to processes for their production and to their use in therapy. In particular, the invention provides immunogenic peptide-**carbohydrate** conjugates useful for generating T cell immunity against tumor-associated **carbohydrate** structures, or against **carbohydrate** structures expressed on infectious agents and/or infected host cells. The immunogenic conjugate comprises a peptide component capable of binding a MHC class I molecule and a **carbohydrate** component having the same immunogenic characteristics of the **carbohydrate** structure on the tumor cell, infectious agent or the infected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 3 OF 18 USPATFULL

1998:86034 Cytokine which is a ligand for OX40.

Baum, Peter R., Seattle, WA, United States

Fanslow, III, William C., Federal Way, WA, United States

Gayle, Richard B., Woodinville, WA, United States

Goodwin, Raymond G., Seattle, WA, United States

Immunex Corporation, Seattle, WA, United States (U.S. corporation)

US 5783665 980721

APPLICATION: US 95-494574 950622 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed a polypeptide (OX40-L) and DNA sequences, vectors and transformed host cells useful in providing OX40-L polypeptides. More particularly, this invention provides isolated murine OX40-L polypeptides that bind to the extracellular binding region of OX40.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 4 OF 18 USPATFULL

1998:68988 Use of interleukin-4 receptors to inhibit biological responses mediated by interleukin-4.

Mosley, Bruce, Seattle, WA, United States

Cosman, David J., Seattle, WA, United States

Park, Linda, Seattle, WA, United States
Beckmann, M. Patricia, Poulsbo, WA, United States
March, Carl J., Seattle, WA, United States
Idzerda, Rejean, Seattle, WA, United States
Immunex Corporation, Seattle, WA, United States (U.S. corporation)
US 5767065 980616
APPLICATION: US 95-466324 950606 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian Interleukin-4 receptor proteins find use in inhibiting biological activities of IL-4. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 5 OF 18 USPATFULL

1998:54459 Biosynthetic binding proteins for immunotargeting.
Huston, James S., Chestnut Hill, MA, United States
Houston, L. L., Oakland, CA, United States
Ring, David B., Redwood City, CA, United States
Oppermann, Hermann, Medway, MA, United States
Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
Creative BioMolecules, Inc., Hopkinton, MA, United States (U.S. corporation)
US 5753204 980519
APPLICATION: US 95-461838 950605 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a formulation for targeting an **epitope** on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a preselected antigen by the binding site of each polypeptide chain when administered to a mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 6 OF 18 USPATFULL

1998:25340 Isolated epstein-barr virus BZLF2 proteins that bind MHC class II beta chains.
Alderson, Mark, Bainbridge Island, WA, United States
Armitage, Richard J., Bainbridge Island, WA, United States
Cohen, Jeffrey I., Silver Spring, MD, United States
Comeau, Michael R., Seattle, WA, United States
Farrah, Theresa M., Seattle, WA, United States
Hutt-Fletcher, Lindsey M., Kansas City, MO, United States
Spriggs, Melanie K., Seattle, WA, United States
Immunex Corporation, Seattle, WA, United States (U.S. corporation)
US 5726286 980310
APPLICATION: US 95-430633 950428 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated viral proteins, and pharmaceutical compositions made

therefrom, are disclosed which are capable of binding to a .beta. chain of a Class II Major Histocompatibility Complex antigen, thereby functioning to inhibit an antigen-specific response. The viral proteins also have superantigen-like activity, and inhibit EBV infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 7 OF 18 USPATFULL

1998:14915 Antibodies that are immunoreactive with interleukin-4 receptors.

Mosley, Bruce, Seattle, WA, United States
Cosman, David J., Seattle, WA, United States
Park, Linda, Seattle, WA, United States
Beckmann, M. Patricia, Poulsbo, WA, United States
March, Carl J., Seattle, WA, United States
Idzerda, Rejean, Seattle, WA, United States
Immunex Corporation, Seattle, WA, United States (U.S. corporation)
US 5717072 980210
APPLICATION: US 95-465169 950605 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian antibodies that are immunoreactive with Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, as well as antibodies that are immunoreactive with IL-4 receptors. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, involves administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 8 OF 18 USPATFULL

1998:14483 Isolated Herpesvirus saimiri proteins that bind MHC Class II molecules.

Yao, Zhengbin, Seattle, WA, United States
Spriggs, Melanie K., Seattle, WA, United States
Alderson, Mark, Bainbridge Island, WA, United States
Armitage, Richard J., Bainbridge Island, WA, United States
Immunex Corporation, Seattle, WA, United States (U.S. corporation)
US 5716623 980210
APPLICATION: US 95-485549 950606 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated viral proteins, and compositions made therefrom, are disclosed which are capable of binding to Class II Major Histocompatibility Complex antigen, thereby functioning to inhibit an antigen-specific response. The isolated viral proteins also act as superantigens.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 9 OF 18 USPATFULL

97:91366 Cytokine designated 4-IBB ligand.

Goodwin, Raymond G., Seattle, WA, United States
Smith, Craig A., Seattle, WA, United States
Alderson, Mark R., Bainbridge Island, WA, United States
Immunex Corporation, Seattle, WA, United States (U.S. corporation)
US 5674704 971007
APPLICATION: US 94-236918 940506 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 10 OF 18 USPATFULL

97:10123 Interleukin-4 receptors.

Mosley, Bruce, Seattle, WA, United States
Cosman, David J., Seattle, WA, United States
Park, Linda, Seattle, WA, United States
Beckmann, M. Patricia, Poulsbo, WA, United States
March, Carl J., Seattle, WA, United States
Idzerda, Rejean, Seattle, WA, United States
Immunex Corporation, Seattle, WA, United States (U.S. corporation)
US 5599905 970204
APPLICATION: US 93-94669 930720 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 11 OF 18 USPATFULL

96:103888 CD27 ligand.

Beckmann, M. Patricia, Poulsbo, WA, United States
Goodwin, Raymond G., Seattle, WA, United States
Giri, Judith G., Seattle, WA, United States
Armitage, Richard J., Bainbridge Island, WA, United States
Immunex Corporation, Seattle, WA, United States (U.S. corporation)
US 5573924 961112
APPLICATION: US 93-106507 930813 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB CD27 ligand (CD27L) polypeptide and DNA sequences, vectors and transformed host cells useful in providing CD27L polypeptides. The CD27L polypeptide binds to the CD27 receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 12 OF 18 USPATFULL

96:60443 Biosynthetic binding proteins for immuno-targeting.

Huston, James S., Chestnut Hill, MA, United States
Houston, L. L., Oakland, CA, United States
Ring, David B., Redwood City, CA, United States
Oppermann, Hermann, Medway, MA, United States
Chiron Corporation, Emeryville, CA, United States (U.S.)

corporation)Creative BioMolecules, Inc., Hopkinton, MA, United States
(U.S. corporation)

US 5534254 960709

APPLICATION: US 93-133804 931007 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a formulation for targeting an **epitope** on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a said preselected antigen by the binding site of each said polypeptide chain when administered to said mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 13 OF 18 USPATFULL

96:43770 Urokinase-type plasminogen activator receptor antibodies.

Dano, Keld, Charlottenlund, Denmark

Ronne, Ebbe, Copenhagen, Denmark

Behrendt, Niels, Bagsvaerd, Denmark

Ellis, Vincent, Copenhagen, Denmark

Hoyer-Hansen, Gunilla, Gentofte, Denmark

Pyke, Charles, Soborg, Denmark

Bruenner, Nils, Virum, Denmark

Cancerforskningsfondet af 1989, Copenhagen, Denmark (non-U.S. corporation)

US 5519120 960521

APPLICATION: US 93-85122 930617 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A monoclonal or polyclonal antibody directed against urokinase plasminogen activator receptor (u-PAR), or a subsequence, analogue or glycosylation variant thereof. Antibodies are disclosed which react with free u-PAR or with complexes between u-PA and u-PAR and which are capable of 1) catching u-PAR in ELISA, or 2) detecting u-PAR, e.g. in blotting, or 3) in radioimmunoprecipitation assay precipitate purified u-PAR in intact or fragment form, or 4) is useful for immunohistochemical detection of u-PAR, e.g. in immunostaining of cancer cells, such as in tissue sections at the invasive front, or 5) inhibits the binding of pro-u-PA and active u-PA and thereby inhibits cell surface plasminogen activation. Methods are disclosed 1) for detecting or quantifying u-PAR, 2) for targeting a diagnostic to a cell containing a u-PAR on the surface, 3) for preventing or counteracting proteolytic activity in a mammal. Methods for selecting a substance suitable for inhibiting u-PA/u-PAR interaction, for preventing or counteracting localized proteolytical activity in a mammal, for inhibiting the invasion and/or metastasis comprise the use of the antibodies and of nude mice inoculated with human cancer cells which are known to invade and/or metastasize in mice and having a distinct color, f.x. obtained by means of an enzyme and a chromogenic substrate for the enzyme, the color being different from the cells of the mouse.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 14 OF 18 USPATFULL

96:29456 Rapid immunoselection cloning method.

Seed, Brian, Boston, MA, United States

Aruffo, Alejandro, Edmonds, WA, United States

The General Hospital Corporation, Charlestown, MA, United States

(U.S. corporation)

US 5506126 960409

APPLICATION: US 93-139273 931018 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A simple and highly efficient method for cloning cDNAs from mammalian expression libraries based on transient expression in mammalian host cells has been discovered. Novel expression vectors allowing highly efficient construction of mammalian cDNA libraries are disclosed. The cloning method of the invention which has been used to clone genes for cell surface antigens of human lymphocytes, has general application in gene cloning. Cell surface antigens cloned according to the present invention have been purified, and the nucleotide and amino acid sequences determined. These antigens have diagnostic and therapeutic utility in immune-mediated infections in mammals, including humans.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 15 OF 18 USPATFULL

95:90459 Cytokine which is a ligand for OX40.

Baum, Peter R., Seattle, WA, United States

Fanslow, III, William C., Federal Way, WA, United States

Gayle, Richard B., Woodinville, WA, United States

Goodwin, Raymond G., Seattle, WA, United States

Immunex Corporation, Seattle, WA, United States (U.S. corporation)

US 5457035 951010

APPLICATION: US 93-97827 930723 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed a polypeptide (OX40-L) and DNA sequences, vectors and transformed host cells useful in providing OX40-L polypeptides. More particularly, this invention provides isolated murine OX40-L polypeptides that bind to the extracellular binding region of OX40.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 16 OF 18 USPATFULL

95:9803 Tumor necrosis factor-induced protein TSG-6.

Lee, Tae H., Piscataway, NJ, United States

Wisniewski, Hans-Georg, Spring Valley, NY, United States

Vilcek, Jan, New York, NY, United States

New York University, New York, NY, United States (U.S. corporation)

US 5386013 950131

APPLICATION: US 93-24868 930301 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pleiotropic pro-inflammatory cytokines, such as TNF and IL-1, induce expression of a protein molecule, termed TSG-6, in connective tissue cells. The TSG-6 protein and functional derivatives thereof, DNA coding therefor, expression vehicles, such as a plasmids, and host cells transformed or transfected with the DNA molecule, and methods for producing the protein and the

DNA are provided. Antibodies specific for the TSG-6 protein are disclosed, as is a method for detecting the presence of TSG-6 protein in a biological sample, using the antibody or another molecule capable of binding to TSG-6 such as hyaluronic acid. A method for detecting the presence of nucleic acid encoding a normal or mutant TSG-6 protein, a method for measuring induction of expression of TSG-6 in a cell using either nucleic acid hybridization or immunoassay, a method for identifying a compound capable of inducing the expression of TSG-6 in a cell, and a method for measuring the ability of a cell to respond to TNF are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 17 OF 18 USPATFULL

94:112895 Method of detecting cancer.

Anderson, Byron E., Morton Grove, IL, United States

Davis, Lyman E., Chicago, IL, United States

Northwestern University, Evanston, IL, United States (U.S. corporation)

US 5376531 941227

APPLICATION: US 92-939830 920903 (7)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a method of screening for gastrointestinal cancer in a mammal comprising: (a) contacting a body fluid taken from the mammal with N3; (b) measuring the amount of antibody to N3 in the body fluid; and (c) determining if the amount of antibody measured in step (b) is higher than the amount of antibody to N3 normally present in the same type of body fluid taken from mammals of the same species that do not have cancer. The invention also provides kits for screening for gastrointestinal cancer in a mammal by measuring the mammal's level of antibodies to N3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 18 OF 18 USPATFULL

93:52683 Interleukin-4 binding protein-.gamma..

Fanslow, William C., Federal Way, WA, United States

Armitage, Richard J., Seattle, WA, United States

Immunex Corporation, Seattle, WA, United States (U.S. corporation)

US 5223605 930629

APPLICATION: US 90-598489 901016 (7)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated and purified Interleukin-4 Binding Protein-.gamma. (IL-4bp.gamma.) and methods for obtaining isolated and purified IL-4bp.gamma..

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1998 ACS

1998:496523 Document No. 129:215424 T cells recognize a glycopeptide derived from type II collagen in a model for rheumatoid arthritis. Broddefalk, Johan; Baecklund, Johan; Almqvist, Fredrik; Johansson, Martin; Holmdahl, Rikard; Kihlberg, Jan (Organic Chemistry, Ume University, Ume, S-901 87, Swed.). J. Am. Chem. Soc., 120(31), 7676-7683 (English) 1998. CODEN: JACSAJ. ISSN: 0002-7863.

0 DENDRIMERIC

707621 POLY

39457 LYSINE

29 POLY LYSINE

(POLY(W)LYSINE)

L2 0 DENDRIMERIC(L) POLY LYSINE

=> fil caplus,.biotech,wpids,uspatful;s (poly lysine or
polylysine)(l)dendrimer?

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.68	119.01
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.03

FILE 'CAPLUS' ENTERED AT 16:29:19 ON 05 NOV 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1998 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:29:19 ON 05 NOV 1998
COPYRIGHT (C) 1998 BIOSIS(R)

FILE 'MEDLINE' ENTERED AT 16:29:19 ON 05 NOV 1998

FILE 'EMBASE' ENTERED AT 16:29:19 ON 05 NOV 1998
COPYRIGHT (C) 1998 Elsevier Science B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:29:19 ON 05 NOV 1998
COPYRIGHT (C) 1998 DERWENT INFORMATION LTD

FILE 'USPATFULL' ENTERED AT 16:29:19 ON 05 NOV 1998
CA INDEXING COPYRIGHT (C) 1998 AMERICAN CHEMICAL SOCIETY (ACS)

L3 19 FILE CAPLUS
L4 5 FILE BIOSIS
L5 6 FILE MEDLINE
L6 7 FILE EMBASE
L7 3 FILE WPIDS
L8 39 FILE USPATFULL

TOTAL FOR ALL FILES

L9 79 (POLY LYSINE OR POLYLYSINE)(L) DENDRIMER?

=> s l9 and carbohydrate peptide

L10 1 FILE CAPLUS
L11 0 FILE BIOSIS
L12 0 FILE MEDLINE
L13 0 FILE EMBASE
L14 0 FILE WPIDS
L15 0 FILE USPATFULL

TOTAL FOR ALL FILES

L16 1 L9 AND CARBOHYDRATE PEPTIDE

=> d cbib abs;s 19 and t epitope?

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1998 ACS

1998:682157 Multiple antigen glycopeptide carbohydrate, vaccine comprising it and its use. Bay, Sylvie; Cantacuzene, Daniele; Leclerc, Claude; Lo-Man, Richard (Institut Pasteur, Fr.). PCT Int. Appl. WO 9843677 A1 19981008, 55 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 98-EP1922 19980327. PRIORITY: US 97-41726 19970327.

AB A **carbohydrate peptide** conjugate comprising: a carrier comprising a **dendrimeric poly-Lysine** enabling multiple epitopes to be covalently attached thereto, at least one peptide comprising one T epitope or several identical or different T epitopes, at least one carbohydrate moiety, or a deriv. thereof, contg. B epitope, provided it is not a sialoside, or several identical or different epitopes. Use of this conjugate for inducing immune response.

L17 1 FILE CAPLUS
L18 0 FILE BIOSIS
L19 0 FILE MEDLINE
L20 0 FILE EMBASE
L21 0 FILE WPIDS
L22 0 FILE USPATFULL

TOTAL FOR ALL FILES

L23 1 L9 AND T EPITOPE?

=> s 123 not 116

L24 0 FILE CAPLUS
L25 0 FILE BIOSIS
L26 0 FILE MEDLINE
L27 0 FILE EMBASE
L28 0 FILE WPIDS
L29 0 FILE USPATFULL

TOTAL FOR ALL FILES

L30 0 L23 NOT L16

=> s lysine and epitope and carbohydrate?

L31 27 FILE CAPLUS
L32 11 FILE BIOSIS
L33 30 FILE MEDLINE
L34 10 FILE EMBASE
L35 1 FILE WPIDS
L36 880 FILE USPATFULL

TOTAL FOR ALL FILES

L37 959 LYSINE AND EPITOPE AND CARBOHYDRATE?

=> s 137 and galactosyl(1)acetyl(1)sdrine

Priority

L38 0 FILE CAPLUS
L39 0 FILE BIOSIS

<-----User Break----->

u

SEARCH ENDED BY USER
SEARCH ENDED BY USER

=> s 137 and galactosyl(1)acetyl(1)serine

L41 0 FILE CAPLUS
L42 0 FILE BIOSIS
L43 0 FILE MEDLINE
L44 0 FILE EMBASE
L45 0 FILE WPIDS
L46 11 FILE USPATFULL

TOTAL FOR ALL FILES

L47 11 L37 AND GALACTOSYL(L) ACETYL(L) SERINE

=> d 1-11 cbib abs;s 137 and (galactosyl or glycosyl)

L47 ANSWER 1 OF 11 USPATFULL

1998:101524 Glycosyltransferases for biosynthesis of oligosaccharides,
and genes encoding them.

Gotschlich, Emil C., New York, NY, United States

The Rockefeller University, New York, NY, United States (U.S.
corporation)

US 5798233 980825

APPLICATION: US 96-683458 960718 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to nucleic acids encoding
glycosyltransferases, the proteins encoded thereby, and to methods
for synthesizing oligosaccharides using the glycosyltransferases
of the invention. In particular, the present application is
directed to identification a glycosyltransferase locus of
Neisseria gonorrhoeae containing five open reading frames for five
different glycosyltransferases. The functionally active
glycosyltransferases of the invention are characterized by
catalyzing reactions such as adding Gal .beta.1.fwdarw.4 to GlcNAc
or Glc; adding GalNAc or GlcNAc .beta.1.fwdarw.3 to Gal; and
adding Gal .alpha.1.fwdarw.4 to Gal. The glycosyltransferases of
the invention are particularly suited to the synthesis of the
oligosaccharides Gal.beta.1.fwdarw.4GlcNAc
.beta.1.fwdarw.3Gal.beta.1.fwdarw.4Glc (a mimic of
lacto-N-neotetraose), GalNAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4Glc
NAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4Glc.beta.1.fwdarw.4 (a mimic
ganglioside), and Gal.alpha.1.fwdarw.4Gal.beta.1.fwdarw.4Glc.beta.
1.fwdarw.4Hep.fwdarw.R (a mimic of the saccharide portion of
globo-glycolipids).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 2 OF 11 USPATFULL

1998:72452 Methods and products for the synthesis of oligosaccharide
structures on glycoproteins, glycolipids, or as free molecules, and
for the isolation of cloned genetic sequences that determine these
structures.

Lowe, John B., Ann Arbor, MI, United States

Legault, Daniel J., Ann Arbor, MI, United States
The Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)
US 5770420 980623

APPLICATION: US 95-525058 950908 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for isolating a gene, comprising:

(i) isolating a cell possessing a post-translational characteristic of interest, said post-translational characteristic being the presence of a membrane-bound oligosaccharide or polysaccharide of interest on the surface of said cell, the presence of a soluble oligosaccharide or polysaccharide of interest in an extract of said cell, or the presence of a particularly glycosyltransferase activity in an extract of said cell;

(ii) creating a genetic library of either cDNA or genomic DNA from the genetic material of said isolated cell;

(iii) transforming host cells with said genetic library; and

(iv) screening said transformed host cells for a host cell containing said post-translational characteristic, thereby obtaining a cell containing said gene, is disclosed. The method can be used to obtain genes encoding glycosyltransferases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 3 OF 11 USPATEFULL

1998:57716 Aptamers specific for biomolecules and methods of making.

Griffin, Linda, Atherton, CA, United States

Albrecht, Glenn, Redwood City, CA, United States

Latham, John, Palo Alto, CA, United States

Leung, Lawrence, Hillsborough, CA, United States

Vermaas, Eric, Oakland, CA, United States

Toole, John J., Burlingame, CA, United States

Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)

US 5756291 980526

APPLICATION: US 95-484192 950607 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for identifying oligomer sequences, optionally comprising modified base, which specifically bind target molecules such as serum proteins, kinins, eicosanoids and extracellular proteins is described. The method is used to generate aptamers that bind to serum Factor X, PDGF, FGF, ICAM, VCAM, E-selectin, thrombin, bradykinin, PGF2 and cell surface molecules. The technique involves complexation of the target molecule with a mixture of oligonucleotides containing random sequences and sequences which serve as primer for PCR under conditions wherein a complex is formed with the specifically binding sequences, but not with the other members of the oligonucleotide mixture. The complex is then separated from uncomplexed oligonucleotides and the complexed members of the oligonucleotide mixture are recovered from the separated complex using the polymerase chain reaction. The recovered oligonucleotides may be sequenced, and successive rounds of selection using complexation, separation, amplification and recovery can be employed. The oligonucleotides can be used for

therapeutic and diagnostic purposes and for generating secondary aptamers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 4 OF 11 USPATFULL

1998:54875 Intercellular adhesion mediators.

Paulson, James C., Sherman Oaks, CA, United States

Perez, Mary S., Carlsbad, CA, United States

Gaeta, Federico C. A., La Jolla, CA, United States

Ratcliffe, Robert M., Carlsbad, CA, United States

Cytel Corporation, San Diego, CA, United States (U.S. corporation)

US 5753631 980519

APPLICATION: US 95-457886 950531 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed towards compositions and methods for reducing or controlling inflammation and for treating inflammatory disease processes and other pathological conditions mediated by intercellular adhesion. The compositions of the invention include compounds that selectively bind selectin receptors, the selectin binding activity being mediated by a **carbohydrate** moiety. The selectin-binding moieties of the invention are derivatives of a sialylated, fucosylated N-acetylglactosamine unit of the Lewis X antigen. Compounds containing a selectin-binding moiety in both monovalent and multivalent forms are included in the invention. The compounds of the invention are provided as pharmaceutical compositions which include, for example, liposomes that carry selectin-binding moieties of the invention. The invention further includes immunoglobulins capable of selectively binding an oligosaccharide ligand that is recognized by a selectin receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 5 OF 11 USPATFULL

1998:1654 Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them.

Gotschlich, Emil C., New York, NY, United States

The Rockefeller University, New York, NY, United States (U.S. corporation)

US 5705367 980106

APPLICATION: US 96-683426 960718 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to nucleic acids encoding glycosyltransferases, the proteins encoded thereby, and to methods for synthesizing oligosaccharides using the glycosyltransferases of the invention. In particular, the present application is directed to identification a glycosyltransferase locus of *Neisseria gonorrhoeae* containing five open reading frames for five different glycosyltransferases. The functionally active glycosyltransferases of the invention are characterized by catalyzing reactions such as adding Gal .beta..fwdarw.4 to GlcNAc or Glc; adding GalNAc or GlcNAc .beta.1.fwdarw.3 to Gal; and adding Gal .alpha.1.fwdarw.4 to Gal. The glycosyltransferases of the invention are particularly suited to the synthesis of the oligosaccharides Gal.beta.1.fwdarw.4GlcNAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4Glc (a mimic of lacto-N-neotetraose), GalNAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4Glc.beta.1.fwdarw.4 (a mimic ganglioside), and

Gal.alpha.1.fwdarw.4Gal.beta.1.fwdarw.4Glc.beta.1.fwdarw.4Hep.fwda
rw.R (a mimic of the saccharide portion of globo-glycolipids).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 6 OF 11 USPATFULL

97:42628 Two-step pretargeting methods using improved biotin-active agent
conjugates.

Reno, John M., Brier, WA, United States
Theodore, Louis J., Lynnwood, WA, United States
Gustavson, Linda M., Seattle, WA, United States
NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
US 5630996 970520
APPLICATION: US 93-122979 930916 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to
pretargeted delivery of diagnostic and therapeutic agents are
disclosed. In particular, methods for radiometal labeling of
biotin and for improved radiohalogenation of biotin, as well as
related compounds, are described. Also, clearing agents,
anti-ligand-targeting moiety conjugates, target cell retention
enhancing moieties and additional methods are discussed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 7 OF 11 USPATFULL

97:36156 Clearing agents useful in pretargeting methods.

Axworthy, Donald B., Brier, WA, United States
Reno, John M., Brier, WA, United States
NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
US 5624896 970429
APPLICATION: US 95-462765 950605 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel clearing agents are provided which comprise biotin analog
containing clearance-directing moieties. Preferably such
clearance-directing moieties endogenously contain or a
rederivatized to expose galactose and/or mannose residues.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 8 OF 11 USPATFULL

97:27275 Hexose derivatized human serum albumin clearing agents.

Axworthy, Donald B., Brier, WA, United States
Reno, John M., Brier, WA, United States
NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
US 5616690 970401
APPLICATION: US 93-133613 931008 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel clearing agents comprising hexose derivatized human serum
albumin and ligand molecule(s) are provided. These clearing agents
are useful in pretargeting methods to clear previously
administered anti-ligand containing conjugates. Preferably, the
hexose is mannose or galactose and the ligand and anti-ligand are
respectively biotin and avidin or streptavidin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 9 OF 11 USPATFULL

97:18284 Biotinidase-resistant biotin-DOTA conjugates.

Axworthy, Donald B., Brier, WA, United States
Theodore, Louis J., Lynnwood, WA, United States
Gustavson, Linda M., Seattle, WA, United States
Reno, John M., Brier, WA, United States
NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
US 5608060 970304
WO 9325240 931223
APPLICATION: US 95-351469 950221 (8)
WO 93-US5406 930607 950221 PCT 371 date 950221 PCT 102(e) date
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Biotinidase-resistant biotin-DOTA conjugates, and methods of use thereof in diagnostic and therapeutic pretargeting methods are provided. These conjugates are useful in diagnosis and treatment of cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 10 OF 11 USPATFULL

96:72801 Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them.

Gotschlich, Emil C., New York, NY, United States
The Rockefeller University, New York, NY, United States (U.S. corporation)
US 5545553 960813
APPLICATION: US 94-312387 940926 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to nucleic acids encoding glycosyltransferases, the proteins encoded thereby, and to methods for synthesizing oligosaccharides using the glycosyltransferases of the invention. In particular, the present application is directed to identification a glycosyltransferase locus of *Neisseria gonorrhoeae* containing five open reading frames for five different glycosyltransferases. The functionally active glycosyltransferases of the invention are characterized by catalyzing reactions such as adding Gal .beta.1.fwdarw.4 to GlcNAc or Glc; adding GalNAc or GlcNAc .beta.1.fwdarw.3 to Gal; and adding Gal .alpha.1.fwdarw.4 to Gal. The glycosyltransferases of the invention are particularly suited to the synthesis of the oligosaccharides Gal.beta.1.fwdarw.4GlcNAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4Glc (a mimic of lacto-N-neotetraose), GalNAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc.beta.1.fwdarw.3Gal.beta.1.fwdarw.4Glc.beta.1.fwdarw.4 (a mimic ganglioside), and Gal.alpha.1.fwdarw.4Gal.beta.1.fwdarw.4Glc.beta.1.fwdarw.4Hep.fwdarw.R (a mimic of the saccharide portion of globo-glycolipids).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L47 ANSWER 11 OF 11 USPATFULL

96:68105 Pretargeting methods and compounds.

Yau, Eric K., Kirkland, WA, United States
Theodore, Louis J., Lynnwood, WA, United States
Gustavson, Linda M., Seattle, WA, United States
NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
US 5541287 960730
APPLICATION: US 94-345811 941122 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to

pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Articles of manufacture useful in pretargeting methods are also discussed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 1 FILE CAPLUS
L49 0 FILE BIOSIS
L50 3 FILE MEDLINE
L51 0 FILE EMBASE
L52 0 FILE WPIDS
L53 123 FILE USPATFULL

TOTAL FOR ALL FILES

L54 127 L37 AND (GALACTOSYL OR GLYCOSYL)

=> s l54 and ((tumour or tumor)(w)antigen or vp1 or poliovirus type 1 or cd8 or neisser? meningit? or haemophil? influenz or streptococc? pneumon? or strpcoc? or tn antigen)

L55 0 FILE CAPLUS
L56 0 FILE BIOSIS
L57 0 FILE MEDLINE
L58 0 FILE EMBASE
L59 0 FILE WPIDS
L60 22 FILE USPATFULL

TOTAL FOR ALL FILES

L61 22 L54 AND ((TUMOUR OR TUMOR)(W) ANTIGEN OR VP1 OR POLIOVIRUS TYPE 1 OR CD8 OR NEISSER? MENINGIT? OR HAEMOPHIL? INFLUENZ OR STREPTOCOCC? PNEUMON? OR STRPCOC? OR TN ANTIGEN)

=> s l61 not (l47 or l16)

L62 0 FILE CAPLUS
L63 0 FILE BIOSIS
L64 0 FILE MEDLINE
L65 0 FILE EMBASE
L66 0 FILE WPIDS
L67 18 FILE USPATFULL

TOTAL FOR ALL FILES

L68 18 L61 NOT (L47 OR L16)

=> d 1-18 cbib abs;d l48 cbib abs;dis his

L68 ANSWER 1 OF 18 USPATFULL

1998:111801 Method of production of antigen-specific glycosylation inhibiting factor.

Ishizaka, Kimishige, La Jolla, CA, United States

Ishii, Yasuyuki, La Jolla, CA, United States

La Jolla Institute for Allergy and Immunology, San Diego, CA, United States (U.S. corporation)

US 5807714 980915

APPLICATION: US 95-416336 950404 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for the recombinant production and for the isolation of

antigen-specific glycosylation inhibiting factor (AgGIF) is provided. Also disclosed is a method for modulating the immune responses in an antigen-specific manner utilizing a AgGIF, comprising soluble non-specific GIF-TCR.alpha. chains which bind to the antigen, and which suppress the immune response in an antigen-specific fashion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 2 OF 18 USPATFULL

1998:111651 Compositions for generating T cell immunity against **carbohydrate** structures.

Jondal, Mikael, Stockholm, Sweden

Astra Aktiebolag, Sodertalje, Sweden (non-U.S. corporation)

US 5807559 980915

APPLICATION: US 93-54860 930427 (8)

PRIORITY: SE 92-1338 920428

SE 92-2553 920907

SE 92-3897 921223

SE 93-1141 930406

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel class of immunologically active compounds, to processes for their production and to their use in therapy. In particular, the invention provides immunogenic peptide-**carbohydrate** conjugates useful for generating T cell immunity against tumor-associated **carbohydrate** structures, or against **carbohydrate** structures expressed on infectious agents and/or infected host cells. The immunogenic conjugate comprises a peptide component capable of binding a MHC class I molecule and a **carbohydrate** component having the same immunogenic characteristics of the **carbohydrate** structure on the tumor cell, infectious agent or the infected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 3 OF 18 USPATFULL

1998:86034 Cytokine which is a ligand for OX40.

Baum, Peter R., Seattle, WA, United States

Fanslow, III, William C., Federal Way, WA, United States

Gayle, Richard B., Woodinville, WA, United States

Goodwin, Raymond G., Seattle, WA, United States

Immunex Corporation, Seattle, WA, United States (U.S. corporation)

US 5783665 980721

APPLICATION: US 95-494574 950622 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed a polypeptide (OX40-L) and DNA sequences, vectors and transformed host cells useful in providing OX40-L polypeptides. More particularly, this invention provides isolated murine OX40-L polypeptides that bind to the extracellular binding region of OX40.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 4 OF 18 USPATFULL

1998:68988 Use of interleukin-4 receptors to inhibit biological responses mediated by interleukin-4.

Mosley, Bruce, Seattle, WA, United States

Cosman, David J., Seattle, WA, United States

Park, Linda, Seattle, WA, United States
Beckmann, M. Patricia, Poulsbo, WA, United States
March, Carl J., Seattle, WA, United States
Idzerda, Rejean, Seattle, WA, United States
Immunex Corporation, Seattle, WA, United States (U.S. corporation)
US 5767065 980616
APPLICATION: US 95-466324 950606 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian Interleukin-4 receptor proteins find use in inhibiting biological activities of IL-4. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 5 OF 18 USPATFULL

1998:54459 Biosynthetic binding proteins for immunotargeting.
Huston, James S., Chestnut Hill, MA, United States
Houston, L. L., Oakland, CA, United States
Ring, David B., Redwood City, CA, United States
Oppermann, Hermann, Medway, MA, United States
Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
Creative BioMolecules, Inc., Hopkinton, MA, United States (U.S. corporation)
US 5753204 980519
APPLICATION: US 95-461838 950605 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a formulation for targeting an **epitope** on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a preselected antigen by the binding site of each polypeptide chain when administered to a mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 6 OF 18 USPATFULL

1998:25340 Isolated epstein-barr virus BZLF2 proteins that bind MHC class II beta chains.
Alderson, Mark, Bainbridge Island, WA, United States
Armitage, Richard J., Bainbridge Island, WA, United States
Cohen, Jeffrey I., Silver Spring, MD, United States
Comeau, Michael R., Seattle, WA, United States
Farrah, Theresa M., Seattle, WA, United States
Hutt-Fletcher, Lindsey M., Kansas City, MO, United States
Spriggs, Melanie K., Seattle, WA, United States
Immunex Corporation, Seattle, WA, United States (U.S. corporation)
US 5726286 980310
APPLICATION: US 95-430633 950428 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated viral proteins, and pharmaceutical compositions made

therefrom, are disclosed which are capable of binding to a .beta. chain of a Class II Major Histocompatibility Complex antigen, thereby functioning to inhibit an antigen-specific response. The viral proteins also have superantigen-like activity, and inhibit EBV infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 7 OF 18 USPATFULL

1998:14915 Antibodies that are immunoreactive with interleukin-4 receptors.

Mosley, Bruce, Seattle, WA, United States

Cosman, David J., Seattle, WA, United States

Park, Linda, Seattle, WA, United States

Beckmann, M. Patricia, Poulsbo, WA, United States

March, Carl J., Seattle, WA, United States

Idzerda, Rejean, Seattle, WA, United States

Immunex Corporation, Seattle, WA, United States (U.S. corporation)

US 5717072 980210

APPLICATION: US 95-465169 950605 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian antibodies that are immunoreactive with Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, as well as antibodies that are immunoreactive with IL-4 receptors. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, involves administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 8 OF 18 USPATFULL

1998:14483 Isolated Herpesvirus saimiri proteins that bind MHC Class II molecules.

Yao, Zhengbin, Seattle, WA, United States

Spriggs, Melanie K., Seattle, WA, United States

Alderson, Mark, Bainbridge Island, WA, United States

Armitage, Richard J., Bainbridge Island, WA, United States

Immunex Corporation, Seattle, WA, United States (U.S. corporation)

US 5716623 980210

APPLICATION: US 95-485549 950606 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated viral proteins, and compositions made therefrom, are disclosed which are capable of binding to Class II Major Histocompatibility Complex antigen, thereby functioning to inhibit an antigen-specific response. The isolated viral proteins also act as superantigens.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 9 OF 18 USPATFULL

97:91366 Cytokine designated 4-IBB ligand.

Goodwin, Raymond G., Seattle, WA, United States

Smith, Craig A., Seattle, WA, United States

Alderson, Mark R., Bainbridge Island, WA, United States

Immunex Corporation, Seattle, WA, United States (U.S. corporation)

US 5674704 971007

APPLICATION: US 94-236918 940506 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel 4-1BB ligand (4-1BB-L) polypeptides and a human cell surface receptor designated 4-1BB that binds 4-1BB-L are provided. Isolated 4-1BB-L-encoding and human 4-1BB-encoding DNA sequences, recombinant expression vectors comprising the isolated DNA sequences, and host cells transformed with the recombinant expression vectors are disclosed, along with methods for producing the novel polypeptides by cultivating such transformed host cells. Soluble forms of the 4-1BB-L or 4-1BB polypeptides are derived from the extracellular domains thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 10 OF 18 USPATFULL

97:10123 Interleukin-4 receptors.

Mosley, Bruce, Seattle, WA, United States

Cosman, David J., Seattle, WA, United States

Park, Linda, Seattle, WA, United States

Beckmann, M. Patricia, Poulsbo, WA, United States

March, Carl J., Seattle, WA, United States

Idzerda, Rejean, Seattle, WA, United States

Immunex Corporation, Seattle, WA, United States (U.S. corporation)

US 5599905 970204

APPLICATION: US 93-94669 930720 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 11 OF 18 USPATFULL

96:103888 CD27 ligand.

Beckmann, M. Patricia, Poulsbo, WA, United States

Goodwin, Raymond G., Seattle, WA, United States

Giri, Judith G., Seattle, WA, United States

Armitage, Richard J., Bainbridge Island, WA, United States

Immunex Corporation, Seattle, WA, United States (U.S. corporation)

US 5573924 961112

APPLICATION: US 93-106507 930813 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB CD27 ligand (CD27L) polypeptide and DNA sequences, vectors and transformed host cells useful in providing CD27L polypeptides. The CD27L polypeptide binds to the CD27 receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 12 OF 18 USPATFULL

96:60443 Biosynthetic binding proteins for immuno-targeting.

Huston, James S., Chestnut Hill, MA, United States

Houston, L. L., Oakland, CA, United States

Ring, David B., Redwood City, CA, United States

Oppermann, Hermann, Medway, MA, United States

Chiron Corporation, Emeryville, CA, United States (U.S.)

corporation)Creative BioMolecules, Inc., Hopkinton, MA, United States
(U.S. corporation)
US 5534254 960709
APPLICATION: US 93-133804 931007 (8)
DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a formulation for targeting an **epitope** on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two polypeptide chains, each of which define single-chain Fv (sFv) binding proteins and have C-terminal tails that facilitate the crosslinking of two sFv polypeptides. The resulting dimeric constructs have a conformation permitting binding of a said preselected antigen by the binding site of each said polypeptide chain when administered to said mammal. The formulation has particular utility in in vivo imaging and drug targeting experiments.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 13 OF 18 USPATFULL

96:43770 Urokinase-type plasminogen activator receptor antibodies.

Dano, Keld, Charlottenlund, Denmark

Ronne, Ebbe, Copenhagen, Denmark

Behrendt, Niels, Bagsvaerd, Denmark

Ellis, Vincent, Copenhagen, Denmark

Hoyer-Hansen, Gunilla, Gentofte, Denmark

Pyke, Charles, Soborg, Denmark

Bruenner, Nils, Virum, Denmark

Cancerforskningsfondet af 1989, Copenhagen, Denmark (non-U.S. corporation)

US 5519120 960521

APPLICATION: US 93-85122 930617 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A monoclonal or polyclonal antibody directed against urokinase plasminogen activator receptor (u-PAR), or a subsequence, analogue or glycosylation variant thereof. Antibodies are disclosed which react with free u-PAR or with complexes between u-PA and u-PAR and which are capable of 1) catching u-PAR in ELISA, or 2) detecting u-PAR, e.g. in blotting, or 3) in radioimmunoprecipitation assay precipitate purified u-PAR in intact or fragment form, or 4) is useful for immunohistochemical detection of u-PAR, e.g. in immunostaining of cancer cells, such as in tissue sections at the invasive front, or 5) inhibits the binding of pro-u-PA and active u-PA and thereby inhibits cell surface plasminogen activation. Methods are disclosed 1) for detecting or quantifying u-PAR, 2) for targeting a diagnostic to a cell containing a u-PAR on the surface, 3) for preventing or counteracting proteolytic activity in a mammal. Methods for selecting a substance suitable for inhibiting u-PA/u-PAR interaction, for preventing or counteracting localized proteolytic activity in a mammal, for inhibiting the invasion and/or metastasis comprise the use of the antibodies and of nude mice inoculated with human cancer cells which are known to invade and/or metastasize in mice and having a distinct color, f.x. obtained by means of an enzyme and a chromogenic substrate for the enzyme, the color being different from the cells of the mouse.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 14 OF 18 USPATFULL

96:29456 Rapid immunoselection cloning method.

Seed, Brian, Boston, MA, United States

Aruffo, Alejandro, Edmonds, WA, United States

The General Hospital Corporation, Charlestown, MA, United States
(U.S. corporation)

US 5506126 960409

APPLICATION: US 93-139273 931018 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A simple and highly efficient method for cloning cDNAs from mammalian expression libraries based on transient expression in mammalian host cells has been discovered. Novel expression vectors allowing highly efficient construction of mammalian cDNA libraries are disclosed. The cloning method of the invention which has been used to clone genes for cell surface antigens of human lymphocytes, has general application in gene cloning. Cell surface antigens cloned according to the present invention have been purified, and the nucleotide and amino acid sequences determined. These antigens have diagnostic and therapeutic utility in immune-mediated infections in mammals, including humans.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 15 OF 18 USPATFULL

95:90459 Cytokine which is a ligand for OX40.

Baum, Peter R., Seattle, WA, United States

Fanslow, III, William C., Federal Way, WA, United States

Gayle, Richard B., Woodinville, WA, United States

Goodwin, Raymond G., Seattle, WA, United States

Immunex Corporation, Seattle, WA, United States (U.S. corporation)

US 5457035 951010

APPLICATION: US 93-97827 930723 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is disclosed a polypeptide (OX40-L) and DNA sequences, vectors and transformed host cells useful in providing OX40-L polypeptides. More particularly, this invention provides isolated murine OX40-L polypeptides that bind to the extracellular binding region of OX40.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 16 OF 18 USPATFULL

95:9803 Tumor necrosis factor-induced protein TSG-6.

Lee, Tae H., Piscataway, NJ, United States

Wisniewski, Hans-Georg, Spring Valley, NY, United States

Vilcek, Jan, New York, NY, United States

New York University, New York, NY, United States (U.S. corporation)

US 5386013 950131

APPLICATION: US 93-24868 930301 (8)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pleiotropic pro-inflammatory cytokines, such as TNF and IL-1, induce expression of a protein molecule, termed TSG-6, in connective tissue cells. The TSG-6 protein and functional derivatives thereof, DNA coding therefor, expression vehicles, such as a plasmids, and host cells transformed or transfected with the DNA molecule, and methods for producing the protein and the

DNA are provided. Antibodies specific for the TSG-6 protein are disclosed, as is a method for detecting the presence of TSG-6 protein in a biological sample, using the antibody or another molecule capable of binding to TSG-6 such as hyaluronic acid. A method for detecting the presence of nucleic acid encoding a normal or mutant TSG-6 protein, a method for measuring induction of expression of TSG-6 in a cell using either nucleic acid hybridization or immunoassay, a method for identifying a compound capable of inducing the expression of TSG-6 in a cell, and a method for measuring the ability of a cell to respond to TNF are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 17 OF 18 USPATEFULL

94:112895 Method of detecting cancer.

Anderson, Byron E., Morton Grove, IL, United States

Davis, Lyman E., Chicago, IL, United States

Northwestern University, Evanston, IL, United States (U.S. corporation)

US 5376531 941227

APPLICATION: US 92-939830 920903 (7)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a method of screening for gastrointestinal cancer in a mammal comprising: (a) contacting a body fluid taken from the mammal with N3; (b) measuring the amount of antibody to N3 in the body fluid; and (c) determining if the amount of antibody measured in step (b) is higher than the amount of antibody to N3 normally present in the same type of body fluid taken from mammals of the same species that do not have cancer. The invention also provides kits for screening for gastrointestinal cancer in a mammal by measuring the mammal's level of antibodies to N3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 18 OF 18 USPATEFULL

93:52683 Interleukin-4 binding protein-.gamma..

Fanslow, William C., Federal Way, WA, United States

Armitage, Richard J., Seattle, WA, United States

Immunex Corporation, Seattle, WA, United States (U.S. corporation)

US 5223605 930629

APPLICATION: US 90-598489 901016 (7)

DOCUMENT TYPE: Utility.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated and purified Interleukin-4 Binding Protein-.gamma. (IL-4bp.gamma.) and methods for obtaining isolated and purified IL-4bp.gamma..

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L48 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1998 ACS

1998:496523 Document No. 129:215424 T cells recognize a glycopeptide derived from type II collagen in a model for rheumatoid arthritis. Broddefalk, Johan; Baecklund, Johan; Almqvist, Fredrik; Johansson, Martin; Holmdahl, Rikard; Kihlberg, Jan (Organic Chemistry, Ume University, Ume, S-901 87, Swed.). J. Am. Chem. Soc., 120(31), 7676-7683 (English) 1998. CODEN: JACSAT. ISSN: 0002-7863.